Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

Antti Siltanen

Analyst

Antti Siltanen portrait

Coverage

Herantis PharmaNexstimFaron PharmaceuticalsNightingale HealthBioretecBiohitOrionModulight

Latest content

ShowingAll content types

Another welfare services country is piloting Nightingale's technology

Analyst Comment 18.12.2025 klo 19.54 by Antti Luiro, Antti Siltanen
Nightingale Health

Investing in the life science sector

Video 18.12.2025 klo 08.47 by Antti Siltanen, Pia Maljanen

New study on benefits of Nightingale blood test in identifying cardiovascular disease risk

Analyst Comment 18.12.2025 klo 10.14 by Antti Luiro, Antti Siltanen
Nightingale Health

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account

Bioretec: Earnings turnaround is slipping further away

Research 17.12.2025 klo 12.05 by Antti Siltanen
Bioretec

Changes in Nightingale’s management team continue

Analyst Comment 15.12.2025 klo 09.59 by Antti Luiro, Antti Siltanen
Nightingale Health

Faron drew down the second tranche of the convertible bond

Analyst Comment 12.12.2025 klo 08.43 by Antti Siltanen
Faron Pharmaceuticals

Nightingale's CFO departs suddenly

Analyst Comment 09.12.2025 klo 07.53 by Antti Luiro, Antti Siltanen
Nightingale Health

New study on the benefits of GastroPanel in guiding treatment

Analyst Comment 09.12.2025 klo 07.52 by Antti Siltanen
Biohit

Faron presented updated BEXMAB data at the ASH meeting

Analyst Comment 09.12.2025 klo 07.50 by Antti Siltanen
Faron Pharmaceuticals

Herantis: Valuation is attractive again

Research 20.11.2025 klo 12.26 by Antti Siltanen
Herantis Pharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.